ERBB2 and non-small cell lung carcinoma: Pan-HER tyrosine kinase inhibitors (TKIs) such as afatinib, pyrotinib, dacomitinib, neratinib, and poziotinib have been evaluated in HER2-positive NSCLC patients, with several of them showing effectiveness (10, 11).